In the phase 4 FOREMOST trial, treatment with apremilast improved both clinical and patient-reported outcomes at week 16 among patients with early oligoarticular PsA.
The following is a summary of “Interstitial Lung Disease in Patients With Rheumatoid Arthritis or Psoriatic Arthritis ...
Wall St. Insights The 2025 Social Security COLA will be only 2.5%. The COLA increase will equal about $50 per person each ...
Here are some strategies for potentially preventing arthritis: Maintain a Healthy Weight: Many cases of arthritis can be ...
The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...
At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...
The following is a summary of “Deciding to Attend the Emergency Department: Experiences of Patients With Inflammatory ...
Machine learning models may be a useful tool for psoriasis severity assessment in clinical settings, despite a need for further research.
Imuldose will be marketed in the United States by Accord BioPharma and is expected to launch in the first half of 2025.
Patients with rheumatoid arthritis (RA) undergoing standard-of-care treatment frequently have persisting pain.
US FDA approves UCB’s 320 mg single-injection device presentations of Bimzelx: Brussels, Belgium Tuesday, October 15, 2024, 13:00 Hrs [IST] UCB, a global biopharmaceutical compa ...
UCB SA (OTCMKTS:UCBJF – Get Free Report) was the recipient of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totalling 419,400 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback